Literature DB >> 225156

[Electroencephalographic assessment of dosage and sleep-profile in a hypnotic Triazolothienodiazepine (author's transl)].

S Kubicki.   

Abstract

We 941, a Triazolodiazepine, has satisfying hypnotic properties. The optimum dosage lies nearly at 0.3 mg. In this dosage the sleep-begin is shortened, the number of nightly wakeness is decreased and the total sleep-time is extended, while the sleep-profile remains unchanged. A normal cycling can be taken as a sign of qualitative good sleep. The REM-percentage is diminished insignificantly and increases again under the continuated therapy. The percentage of deep sleep increases by 0.3 mg. The subjective presentations confirm the melioration of sleep. In higher dosages troubles occur as decrease of deep-sleep stage and deteriorations of feeling. Remarkable is the withdrawal effect after 1.0 mg with an initial and a dissociated REM. However, such strong disturbances couldn't be observed in the carried on therapy with 0.3 mg.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 225156

Source DB:  PubMed          Journal:  EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb        ISSN: 0012-7590


  4 in total

1.  Residual effects of flurazepam and brotizolam on psychomotor performance.

Authors:  H Krueger; W Müller-Limmroth
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

2.  Quantitative pharmaco-EEG and performance after administration of brotizolam to healthy volunteers.

Authors:  B Saletu; J Grünberger; L Linzmayer
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Elimination of brotizolam in elderly patients after multiple doses.

Authors:  W D Bechtel; E Goetzke
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic.

Authors:  M S Langley; S P Clissold
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.